Pharmaceuticals

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new drug promises the brain-rewiring benefits of psychedelics without the trip. Can Clearmind Medicine's CMND-100 transform addiction treatment?

Sanofi deepens its partnership with Owkin, licensing its 'K Pro' platform to build autonomous AI agents. A look at the strategy behind this major bet.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

A blockbuster drug for chronic illness gets a generic rival, promising huge savings. But is it just about price? A deep dive into the strategy behind the new pill.

Australian biotech Gelteq is opening a China R&D hub to chase explosive growth, but its bold move into a $60B market comes with significant geopolitical risks.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

Scilex sets a date to pay out Semnur stock to its shareholders. We dig into whether this is a true value unlock or a move born from financial pressure.

New data showing a 300% spike in demand for Burmese prescription translations is a stark economic signal of a deeper demographic shift challenging U.S. healthcare.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

A key regulatory win in Japan propels a potential first-ever treatment for Netherton Syndrome, but the real story is the high-wire act of global commercialization.